FDA delays Decision on Moderna vaccine for adolescents citing heart problems, Yet Pfizer authorized for teens, despite higher number of myocarditis reports
By Megan Redshaw
The U.S. Food and Drug Administration (FDA) said on Oct. 15 it was delaying a decision on authorizing Moderna’s COVID vaccine for adolescents while the agency assesses whether the shot could increase the risk of myocarditis, a heart inflammatory condition, the Wall Street Journal reported.
In June, the FDA added a warning to the literature accompanying Pfizer and Moderna mRNA COVID vaccines, to indicate an increased risk of myocarditis.
However in May, a few weeks before the FDA added the warning, the agency authorized Pfizer’s COVID vaccine for ages 12 to 17, despite the known increased risk of myocarditis...
Read more: https://childrenshealthdefense.org/defender/fda-moderna-pfizer-covid-vaccine-teens-myocarditis/?utm_source=salsa&eType=EmailBlastContent&eId=798eab5b-477f-4720-9579-1cc7fa3150d8